Rigel Pharmaceuticals FIT Phase 3 ITP Study Results October 2016

Rigel Pharmaceuticals conference call presentation on results from the FIT Phase 3 clinical study for immune thrombocytopenia (ITP) treatment. The presentation includes an overview of the trial program, detailed results commentary, and Q&A with executives including CEO D. Vance and clinical experts.